# A Study of LY3561774 in Participants With Mixed Dyslipidemia

> **NCT05256654** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 205 (actual)

## Conditions studied

- Dyslipidemias
- Lipid Metabolism Disorders
- Metabolic Diseases
- Hyperlipoproteinemia

## Interventions

- **DRUG:** LY3561774
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05256654
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-20
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-05-23
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256654, "A Study of LY3561774 in Participants With Mixed Dyslipidemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05256654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*